Pulmonary hypertension in Heart failure with preserved Ejection Fraction (PH-HFpEF)
TECXTectonic TherapeuticCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for TX45 in Pulmonary hypertension in Heart failure with preserved Ejection Fraction (PH-HFpEF) . The expected timing is based on the latest available company guidance and may change.
APEX trial. 9/19/24- Topline Ph1a data reported. Ph2 trial initiated. 3/20/25- Started Ph1b part B enrollment. 5/17/25- 24-wk topline results in 2026. 10/29/25– Topline Ph1b Part B data reported. 02/26/26:- APEX Ph2 trial ongoing in PH-HFpEF; 24-week topline results expected in 2026. 05/07/26:- APEX Ph2 enrollment near complete; topline results expected late Q4 2026 or early Q1 2027. 06/10/26:- APEX Ph2 enrollment complete. Topline results expected Early Q1 2027. 08/06/26:- APEX enrollment completed; IDMC recommended continuing trial; topline results expected Early Q1 2027.
Verification
Confirm timing and program details against the company announcement or filing.